ICMJE DISCLOSURE FORM

Date: 04/08/2023

Your Name: Ayse Ece Cali Daylan

Manuscript Title: Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail

Manuscript number (if known): TLCR-23-245

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: pastXNoneXNone	36 months
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	X_None	
	ease summarize the above controls.	onflict of interest in the fol	lowing box:

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 04/08/2023

Your Name: Balazs Halmos

Manuscript Title: Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail

Manuscript number (if known): TLCR-23-245

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			_
	medical writing, article processing charges, etc.)			_
	No time limit for this item.			+
				-
				†
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Boehringer Ingelheim		
		Astra Zeneca		
		Merck		
		BMS		
		Advaxis		
		Amgen		
		AbbVie		
		Daiichi		
		Pfizer		

		GSK	
		Beigene	
		Janssen	
		Numab	
		Arrivent	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	V. None	
6	Payment for expert testimony	_XNone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
	Intectings and/or traver		
_			
8	Patents planned, issued or	XNone	
	pending		
	5		
9	Participation on a Data	Astra Zeneca	
	Safety Monitoring Board or Advisory Board	Boehringer Ingelheim	
	Advisory Board	Apollomics	
		Janssen	
		Takeda	
		Merck	
		BMS Genentech	
		Pfizer	
		Eli-Lilly	
		TPT	
		Arcus	
		Aicus	
10	Leadership or fiduciary role	X_None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	,		
12	Receipt of equipment,	XNone	
12			

	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

B. H. has grants or contracts from Boehringer Ingelheim, Astra Zeneca, Merck, BMS, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GSK, Beigene, Janssen, Numab and Arrivent and is on
monitoring/advisory boards of Astra Zeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, BMS, Genentech, Pfizer, Eli-Lilly, TPT and Arcus.

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.